19 completed, 4 unknown, 2 active not recruiting, 2 not yet recruiting. 31 Phase 2, 8 Phase 1, 5 Phase 3.
Follow Dosage Forms: new trials by email Literature Review of Dosage Forms trials Research Report on Dosage Forms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dynamic Treatment Regimes for Opioid Use Disorder Medication for opioid use disorder, psychotherapy - Opioid Use Disorder | Phase 2 | Not yet recruiting | Brigham and Women's Hospital | 75 | 2028-07-01 | 2025-11-04 |
| Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children Trimethoprim-sulfamethoxazole (TMP/SMX), Metronidazole, Amoxicillin-Clavulanate (4:1 formulation) - Small Intestine Bacterial Overgrowth | Phase 2 | Active not recruiting | University of Virginia | 60 | 2026-04-18 | 2026-11-02 |
| Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV Patients BPR-101 capsules:Investigational product for the treatment of BV, Placebo：matching the investigational product in appearance, dosage form, and route of administration - Bacterial Vaginosis | Phase 2 | Not yet recruiting | Chengdu Syncor Pharmaceutical Co., Ltd. | 80 | 2026-04-15 | 2026-03-19 |
| A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid Amantadine, Physical, Occupational, Speech Therapy, Provider Counseling - Long COVID, Post-Acute COVID-19 Syndrome | Phase 2 | Withdrawn | University of Texas Southwestern Medical Center | 2025-06-01 | 2025-08-26 | |
| Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID) Inflammation (I), Inflammation (II), Inflammation (III) - Covid19 Virus Infection | Phase 1 / Phase 2 | Recruiting | All Natural Medicine Clinic, LLC | 100 | 2025-01-01 | 2025-02-19 |
| Efficacy and Safety of HB-1 for Panic Disorder HB-1, Telmisartan Only Product in Oral Dose Form, Verapamil Only Product in Oral Dose Form - Panic Disorder, Mental Illness | Phase 2 | Terminated | HB BioTech, LLC | 170 | 2024-10-29 | 2026-09-24 |
| Iron Administration Via Colonic TET Combined With WMT for ID Ferrous Lactate, Iron sucrose, 0.9% NaCl solution - Iron Deficiency Anemia in Childbirth | Phase 2 | Unknown | The Second Hospital of Nanjing Medical University | 60 | 2024-07-25 | 2024-07-22 |
| Effect of Vitamin C on Postoperative Pulmonary Complications After Intracranial Tumor Surgery Ascorbic acid, Saline - Ascorbic Acid, Neurosurgical Procedures | Phase 2 | Unknown | Qianfoshan Hospital | 86 | 2024-06-01 | 2024-05-20 |
| Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a) Naltrexone and Bupropion (NB) medication, Placebo - Loss-of-Control Eating, Obesity/Overweight | Phase 2 / Phase 3 | Completed | Yale University | 24 | 2022-06-10 | 2026-08-26 |
| Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN Selumetinib granule formulation, Selumetinib capsule formulation - Neurofibromatosis Type 1 | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 36 | 2022-01-21 | 2026-08-13 |
| Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b) Lisdexamfetamine Dimesylate (Medication), Placebo - Loss-of-control Eating, Obesity/Overweight | Phase 2 / Phase 3 | Completed | Yale University | 16 | 2022-01-02 | 2026-08-06 |
| EXHIT ENTRE Comparative Effectiveness Trial Extended Release Buprenorphine, Treatment as Usual - Substance Use Disorder, Opioid Use Disorder, Moderate | Phase 2 / Phase 3 | Completed | Gavin Bart | 344 | 2021-08-09 | 2025-12-09 |
| World Health Organization (WHO) , COVID19 Case Series of Post Covid 19 Rhino Orbito Cerebral Mucormycosis in Egypt debridment - Mucormycosis; Rhinocerebral (Etiology), COVID-19 | Phase 1 / Phase 2 | Completed | Nasser Institute For Research and Treatment | 35 | 2021-05-23 | 2024-02-20 |
| Clinical Study to Evaluate the Effect of Food Supplement in People Infected With Coronavirus LCLT : 68% elemental L-carnitine and 32 % Tartric acid, Placebo - COVID-19 Virus Infection | Phase 2 | Completed | SENAI CIMATEC | 224 | 2021-03-01 | 2022-07-07 |
| Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM) Hydroxychloroquine Only Product in Oral Dose Form - Sars-CoV2, Coronavirus Infection | Phase 2 / Phase 3 | Unknown | University of Malaga | 1930 | 2020-09-01 | 2020-09-29 |
| A Phase 2a Trial of FOL-005 Topical Formulations to Investigate Hair Growth Potential and Safety in Healthy Male Volunteers Topical formulation - Androgenetic Alopecia | Phase 2 | Completed | Follicum AB | 209 | 2020-06-24 | 2021-03-01 |
| Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma Medication (A specification is listed under each arm), Patient reported outcomes measurement - Metastatic Renal Cell Carcinoma, Kidney Neoplasm | Phase 2 | Unknown | Herlev and Gentofte Hospital | 30 | 2020-03-06 | 2020-11-25 |
| Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006) V184, Placebo - Chikungunya Virus Infection | Phase 2 | Completed | Themis Bioscience GmbH | 41 | 2019-07-16 | 2022-09-08 |
| Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection ChAd155-hIi-HBV low dose formulation, ChAd155-hIi-HBV high dose formulation, HBc-HBs/AS01B-4 low dose formulation - Hepatitis B, Chronic | Phase 1 / Phase 2 | Terminated | GlaxoSmithKline | 236 | 2019-03-28 | 2026-02-20 |
| A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk Lymphoma Cal-1 (LVsh5/C46) drug product - HIV-1 Infection | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 2 | 2019-01-15 | 2025-11-20 |
Showing 20 of 31. Sign in to see all of them.
COVID-19 (4) · Dengue (2) · Leukemia (2) · Obesity (2) · Opioid-Related Disorders (2) · Overweight (2) · Severe Dengue (2) · Alopecia (1) · Carcinoma, Renal Cell (1) · Chikungunya Fever (1) · Coronary Restenosis (1) · Coronavirus Infections (1) · Cough (1) · Depression (1) · Fever (1)
Genzyme, a Sanofi Company (3) · GlaxoSmithKline (2) · Sanofi Pasteur, a Sanofi Company (2) · University Hospital, Saarland (2) · Yale University (2) · All Natural Medicine Clinic, LLC (1) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · Brigham and Women's Hospital (1) · Chengdu Syncor Pharmaceutical Co., Ltd. (1) · Follicum AB (1) · Gavin Bart (1) · HB BioTech, LLC (1) · Herlev and Gentofte Hospital (1) · Johns Hopkins University (1)
United States (13) · Germany (5) · China (3) · Belgium (2) · Brazil (2) · France (2) · Netherlands (2) · Puerto Rico (2) · Spain (2) · Thailand (2) · United Kingdom (2) · Australia (1) · Bangladesh (1) · Colombia (1) · Denmark (1)
Amy Mathews, M.D. (1) · Ann Melvin, MD, MPH (1) · Bruno Scheller, MD (1) · Carlos Grilo, PhD (1) · Claudia M Campbell, Ph.D. (1) · Dong Wang, M.D (1) · Faming Faming, PhD (1) · FengXia Xue, Doctor of Medicine(M.D.) (1) · Gavin Bart, MD,PhD (1) · Ida Marie L Rasmussen, MD (1) · Jeffrey R Donowitz, MD (1)
PMID 15141377, PMID 18536865, PMID 18779447, PMID 20439832, PMID 22440499, PMID 23769413, PMID 30986790, PMID 31464558, PMID 32240634, PMID 32391299, PMID 33626291, PMID 33710614, PMID 36107483, PMID 39623502, PMID 41481837, PMID 41592259, PMID 42573020
R01DK126637 (2), 2008 (1), 2015 (1), 2017 (1), 2019 (1), 5UG1DA040316-05 (1), K01DA061975 (1), R01DA042751 (1), R01HD113733 (1), R01MH069887 (1)